Pulmonx Co. (NASDAQ:LUNG) Stock Position Reduced by Boothbay Fund Management LLC

Boothbay Fund Management LLC decreased its holdings in shares of Pulmonx Co. (NASDAQ:LUNG - Free Report) by 22.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 212,980 shares of the company's stock after selling 63,206 shares during the period. Boothbay Fund Management LLC owned about 0.54% of Pulmonx worth $1,446,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. 272 Capital LP bought a new stake in shares of Pulmonx during the 3rd quarter valued at about $48,000. R Squared Ltd acquired a new position in Pulmonx in the fourth quarter valued at approximately $46,000. Stifel Financial Corp bought a new position in shares of Pulmonx during the fourth quarter valued at approximately $81,000. SG Americas Securities LLC grew its holdings in shares of Pulmonx by 27.0% during the fourth quarter. SG Americas Securities LLC now owns 15,555 shares of the company's stock valued at $106,000 after purchasing an additional 3,310 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in shares of Pulmonx by 48.7% during the 4th quarter. Wells Fargo & Company MN now owns 18,418 shares of the company's stock worth $125,000 after purchasing an additional 6,033 shares during the period. Institutional investors own 91.04% of the company's stock.

Wall Street Analyst Weigh In

LUNG has been the subject of a number of recent research reports. Canaccord Genuity Group lowered their price objective on Pulmonx from $16.00 to $15.00 and set a "buy" rating for the company in a research note on Thursday. Citigroup began coverage on shares of Pulmonx in a research report on Monday, March 10th. They issued a "buy" rating on the stock. Morgan Stanley initiated coverage on shares of Pulmonx in a research report on Monday, March 10th. They issued an "equal weight" rating for the company. D. Boral Capital reiterated a "buy" rating and set a $17.00 price objective on shares of Pulmonx in a research report on Thursday. Finally, Jefferies Financial Group began coverage on Pulmonx in a research report on Monday, March 10th. They issued a "buy" rating on the stock. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Pulmonx currently has a consensus rating of "Moderate Buy" and a consensus target price of $12.07.

Insider Buying and Selling

In other Pulmonx news, insider Geoffrey Beran Rose sold 5,779 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $7.13, for a total transaction of $41,204.27. Following the completion of the sale, the insider now directly owns 285,278 shares of the company's stock, valued at approximately $2,034,032.14. This represents a 1.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Glendon E. French III sold 55,453 shares of Pulmonx stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $8.28, for a total transaction of $459,150.84. Following the completion of the transaction, the director now directly owns 1,011,974 shares in the company, valued at approximately $8,379,144.72. This trade represents a 5.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 145,660 shares of company stock worth $1,128,484. Corporate insiders own 6.80% of the company's stock.

Pulmonx Price Performance

LUNG remained flat at $3.77 during trading on Friday. The company's stock had a trading volume of 902,554 shares, compared to its average volume of 312,901. The stock has a fifty day simple moving average of $6.43 and a 200 day simple moving average of $6.53. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. The stock has a market cap of $151.73 million, a price-to-earnings ratio of -2.62 and a beta of 0.65. Pulmonx Co. has a 12-month low of $3.61 and a 12-month high of $10.01.

Pulmonx (NASDAQ:LUNG - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.01. The company had revenue of $22.54 million during the quarter, compared to the consensus estimate of $22.03 million. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. On average, research analysts forecast that Pulmonx Co. will post -1.55 EPS for the current fiscal year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.